FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387207941> ?p ?o ?g. }

• W4387207941 endingPage "S60" @default.
• W4387207941 startingPage "S60" @default.
• W4387207941 abstract "Liver-metastasis-directed SBRT (LM-SBRT) alone provides durable local control for liver metastases with low rates of toxicity when adhering to established dose constraints. Whether these constraints are sufficient in the context of concurrent ICI is not established. To determine whether LM-SBRT contributes to hepatotoxic adverse events (HAE) in patients receiving ICI, we analyzed potential predictors of HAE in a prospectively evaluated cohort of clinical trial patients treated with both SBRT and ICI.Patients with metastatic solid tumors were included from three trials of multi-site SBRT with ICI given concurrently or shortly after SBRT provided they received all study treatments and were monitored for adverse events. ICI agents included pembrolizumab alone or dual agent ICI with nivolumab and either cabiralizumab, urelumab, or ipilimumab. LM-SBRT was delivered to 45 Gy in 3 fr with mean liver dose (MLD) limited to 16 Gy and <700 cc of liver receiving 17.1 Gy. HAE were defined using CTCAE 4.0 as: elevation of AST, ALT, bilirubin or alkaline phosphatase; autoimmune hepatitis; hepatic failure; or cholecystitis. HAE were included if rated at least possibly related to treatment by the trial monitoring committee. Cumulative incidence (CI) of HAE was modeled with death as a competing risk. Competing risks regression was performed using Fine-Gray modeling.Two hundred thirteen patients were evaluable. Median follow-up was 10 months. Median age was 61, 90 had liver metastases at treatment, 65 received SBRT to a liver lesion, 15 had underlying liver disease (cirrhosis or hepatic steatosis) and 13 patients had a primary liver cancer. Dual agent ICI was given to 97 patients. Table 1 shows CI at 6 months of grades 1-4 HAE in all patients, LM-SBRT patients and non-liver SBRT patients (NL-SBRT). None experienced grade 5 HAE. There was no significant difference in CI of any grade of HAE between LM-SBRT and NL-SBRT patients. This was also true when comparing LM-SBRT patients to NL-SBRT patients with <0.1 Gy MLD. ICI dose reduction or cessation due to HAE occurred in 4 patients, none of whom received LM-SBRT. On univariate analysis, underlying liver disease and dual agent ICI were significantly associated with grade 2+ HAE while age, LM-SBRT, MLD, primary liver cancer and presence of liver metastases at treatment were not. On multivariate analysis, underlying liver disease and dual agent ICI remained significantly associated with grade 2+ HAE (HR: 6.7, 95% CI 2.3 - 19.1; 4.7, 95% CI 1.7 - 13.0). LM-SBRT and MLD were not significant on MVA.LM-SBRT did not significantly increase the risk for hepatotoxicity in patients receiving ICI when respecting the above dose constraints. Risk for hepatotoxicity appears to be driven by dual agent ICI and underlying liver disease." @default.
• W4387207941 created "2023-09-30" @default.
• W4387207941 creator A5020288068 @default.
• W4387207941 creator A5026229770 @default.
• W4387207941 creator A5030967817 @default.
• W4387207941 creator A5042717822 @default.
• W4387207941 creator A5045294159 @default.
• W4387207941 creator A5055476105 @default.
• W4387207941 creator A5062335617 @default.
• W4387207941 date "2023-10-01" @default.
• W4387207941 modified "2023-10-17" @default.
• W4387207941 title "Predictors of Hepatotoxicity in Patients with Metastatic Solid Tumors Treated with Immune Checkpoint Inhibition (ICI) and Liver-Directed SBRT" @default.
• W4387207941 doi "https://doi.org/10.1016/j.ijrobp.2023.06.357" @default.
• W4387207941 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37784536" @default.
• W4387207941 hasPublicationYear "2023" @default.
• W4387207941 type Work @default.
• W4387207941 citedByCount "0" @default.
• W4387207941 crossrefType "journal-article" @default.
• W4387207941 hasAuthorship W4387207941A5020288068 @default.
• W4387207941 hasAuthorship W4387207941A5026229770 @default.
• W4387207941 hasAuthorship W4387207941A5030967817 @default.
• W4387207941 hasAuthorship W4387207941A5042717822 @default.
• W4387207941 hasAuthorship W4387207941A5045294159 @default.
• W4387207941 hasAuthorship W4387207941A5055476105 @default.
• W4387207941 hasAuthorship W4387207941A5062335617 @default.
• W4387207941 hasConcept C121608353 @default.
• W4387207941 hasConcept C126322002 @default.
• W4387207941 hasConcept C141071460 @default.
• W4387207941 hasConcept C151730666 @default.
• W4387207941 hasConcept C197934379 @default.
• W4387207941 hasConcept C2776029263 @default.
• W4387207941 hasConcept C2777075537 @default.
• W4387207941 hasConcept C2777701055 @default.
• W4387207941 hasConcept C2779343474 @default.
• W4387207941 hasConcept C2780030458 @default.
• W4387207941 hasConcept C2780057760 @default.
• W4387207941 hasConcept C2992208098 @default.
• W4387207941 hasConcept C71924100 @default.
• W4387207941 hasConcept C72563966 @default.
• W4387207941 hasConcept C86803240 @default.
• W4387207941 hasConcept C88879693 @default.
• W4387207941 hasConcept C90924648 @default.
• W4387207941 hasConceptScore W4387207941C121608353 @default.
• W4387207941 hasConceptScore W4387207941C126322002 @default.
• W4387207941 hasConceptScore W4387207941C141071460 @default.
• W4387207941 hasConceptScore W4387207941C151730666 @default.
• W4387207941 hasConceptScore W4387207941C197934379 @default.
• W4387207941 hasConceptScore W4387207941C2776029263 @default.
• W4387207941 hasConceptScore W4387207941C2777075537 @default.
• W4387207941 hasConceptScore W4387207941C2777701055 @default.
• W4387207941 hasConceptScore W4387207941C2779343474 @default.
• W4387207941 hasConceptScore W4387207941C2780030458 @default.
• W4387207941 hasConceptScore W4387207941C2780057760 @default.
• W4387207941 hasConceptScore W4387207941C2992208098 @default.
• W4387207941 hasConceptScore W4387207941C71924100 @default.
• W4387207941 hasConceptScore W4387207941C72563966 @default.
• W4387207941 hasConceptScore W4387207941C86803240 @default.
• W4387207941 hasConceptScore W4387207941C88879693 @default.
• W4387207941 hasConceptScore W4387207941C90924648 @default.
• W4387207941 hasIssue "2" @default.
• W4387207941 hasLocation W43872079411 @default.
• W4387207941 hasLocation W43872079412 @default.
• W4387207941 hasOpenAccess W4387207941 @default.
• W4387207941 hasPrimaryLocation W43872079411 @default.
• W4387207941 hasRelatedWork W2287821501 @default.
• W4387207941 hasRelatedWork W2466451466 @default.
• W4387207941 hasRelatedWork W2518422528 @default.
• W4387207941 hasRelatedWork W2580215808 @default.
• W4387207941 hasRelatedWork W2985211404 @default.
• W4387207941 hasRelatedWork W3000961096 @default.
• W4387207941 hasRelatedWork W3016822790 @default.
• W4387207941 hasRelatedWork W3103843449 @default.
• W4387207941 hasRelatedWork W4206403947 @default.
• W4387207941 hasRelatedWork W4319827755 @default.
• W4387207941 hasVolume "117" @default.
• W4387207941 isParatext "false" @default.
• W4387207941 isRetracted "false" @default.
• W4387207941 workType "article" @default.